TSTickerStarGet alerts

Aptevo reports preclinical data for APVO451, APVO452 and APVO711 at SITC 2026

Aptevo said APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation in preclinical studies under immunosuppressive conditions. It also said APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings. The data were presented at the SITC 2026 Annual Meeting on November 7, 2026; no financial results or guidance were disclosed.

Share this story

Key takeaways

  • Preclinical activity: APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation under immunosuppressive conditions.

  • APVO451 and APVO452 design: Both molecules combine CD40 activation with T-cell engagement.

  • APVO711 mechanism: Preclinical findings showed CD40 activation combined with PD-L1 checkpoint blockade.

  • Development timeline: APVO451 and the first Niowave radiopharmaceutical program are expected to advance into IND-enabling studies in 2027.

  • Niowave collaboration: Aptevo is developing up to three radiopharmaceutical oncology programs, with the first expected to target nectin-4.

  • Evidence scope: The reported findings were preclinical and did not establish clinical efficacy or safety in patients.

  • Pipeline: Aptevo reported eight pipeline candidates created using its ADAPTIR and ADAPTIR-FLEX platforms.

Key metrics

APVO451 and APVO452 preclinical activityPreclinical studies
Tumor-cell killing and T-cell activation under immunosuppressive conditions
APVO711 preclinical activityPreclinical studies
CD40 activation combined with PD-L1 checkpoint blockade
Niowave radiopharmaceutical oncology programsAs of November 9, 2026
Up to 3
Expected IND-enabling study timing for APVO451 and first Niowave program2027
2027
Pipeline candidatesAs of November 9, 2026
8

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow APVO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert